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Background: Drug efflux (for example, P-glycoprotein 
[P-gp], multidrug resistance-associated proteins [MRPs] 
and breast cancer resistance protein [BCRP]) and influx 
(for example, human organic anion transporting polypep-
tide [hOCTP] or human organic anion transporting 
polypeptide [hOATP]) transporters alter the cellular con-
centrations of some HIV protease inhibitors (HPIs). Here, 
we studied the lipophilicity and uptake of [3H]-atazanavir 
(ATV) in CEM (parental), CEMVBL (P-gp-overexpressing), 
CEME1000 (MRP1-overexpressing) and peripheral blood 
mononuclear cells (PBMCs), and evaluate the effects of 
modulators of drug transporters on uptake.
Methods: Lipophilicity was measured by octanol/saline 
partition method. The influence of influx/efflux trans-
porters on uptake was evaluated in the absence and 
presence of inhibitors of P-gp (GPV031), P-gp/BCRP (tar-
iquidar and GF120918), P-gp/MRP1 (dipyridamole and 
daidzein), MRP1/2 (frusemide and genistein), hOATP/
hOCTP (estrone-3-sulfate [E-3-S]) and hOATP/hOCTP/
MRP (probenecid). The effects of a number of HPIs on 
uptake were also evaluated. Data from digitonin permea-
bilized cells allowed the evaluation of the contribution of 
cellular binding to total drug uptake, whereas the inhibi-
tory effect of ATV on P-gp was assessed by daunomycin 
efflux/uptake assays.
Results: [3H]-ATV is lipophilic and accumulates in the 
cultured cells as follows: CEM>CEME1000>CEMVBL. Tariq-
uidar, GF120918 and daidzein significantly increased the 
uptake of [3H]-ATV in the cultured cells. By contrast, only 
daidzein and tipranavir significantly increased uptake in 
PBMCs, with tariquidar and frusemide devoid of effects, 
whereas dipyridamole, E-3-S, GPV031 and genistein sig-
nificantly decreased accumulation. ATV inhibits P-gp 
activity; manipulation of uptake with digitonin suggests 
binding of [3H]-ATV to P-gp.
Conclusions: [3H]-ATV is lipophilic, a P-gp, MRP and 
hOATP substrate and an inhibitor of P-gp. Concomitant 
administration of ATV with drugs and dietary components 
(for example, daidzein and genistein) that interact with 
these transporters could alter its pharmacokinetics.
HIV protease inhibitors (HPIs) in combination with 
other antiretrovirals (for example, reverse transcriptase 
inhibitors) play a pivotal role in the management of 
HIV-infected patients. The therapeutic effects of these 
drugs is dependent on their cellular accumulation, 
which is in part affected by the expression of ATP bind-
ing cassette family of drug efflux transporters, such as 
P- glycoprotein (P-gp), multidrug resistance-associated 
proteins (MRPs) and breast cancer resistance protein 
(BCRP) [1–3]. In addition, there are some known ani-
onic and cationic transporters, such as human organic 
anion transporting polypeptide (hOATP) and human 
organic cation transporters (hOCTs), respectively, 
which mediate the influx/elimination of many clinically 
important drugs and xenobiotics, and these have been 
shown to limit the accumulation of some HPIs [2,4–6]. 
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All these transporters are differentially expressed in 
the liver, kidney, circulating lymphocytes, brain, testes 
and intestines – sites important in drug disposition, or 
which might act as sanctuary for the replicating virus 
and/or support viral replication. Clearly, low intracel-
lular/plasma drug concentration or altered distribution 
within these sites could affect clinical outcome.
The transporters work in concert to control the bio-
availability of clinically important drugs and endog-
enous compounds. Thus, together with the cytochrome 
P450 enzymes, these transporters are important deter-
minants of drug–drug interactions, drug efficacy and 
toxicity [7]. Indeed, previous studies have shown 
the oral availability, brain, and fetal penetration of 
saquinavir (SQV) to be limited by P-gp [8,9]. Simi-
larly, the intracellular accumulations of a number of 
HPIs have been shown to be limited by P-gp, MRP1, 
MRP2 and BCRP [1,2,8–19]. There is ample evidence 
that some HPIs also induce and inhibit the expression 
of drug efflux transporters, such as P-gp, MRP1/2 and 
BCRP [12,16,20–25]. However, the role of BCRP in 
the efflux of HPIs is equivocal [1,3,24–27]; there is 
evidence that BCRP induces resistance to nucleoside 
reverse transcriptase inhibitors [27].
We have shown that the intracellular concentrations 
of HPIs are amenable to manipulation by coadmin-
istration with inhibitors of drug efflux transporters 
[1,2,13]. A potential use of such agents would be to 
enhance intestinal drug absorption and increase drug 
penetration to biologically important protective bar-
riers, such as the blood–brain, blood–cerebrospinal 
fluid, maternal–fetal barriers, testes, and within cir-
culating lymphocytes that might be impenetrable to 
these drugs. To this end, because ritonavir-mediated 
inhibition of cytochrome P450 (CYP3A4/CYP2D6) 
and possibly P-gp has been shown to increase expo-
sure to coadministered HPIs, ritonavir (RTV)-boosted 
HPIs are a standard component of antiretroviral regi-
men [28]. Interestingly, we and others have recently 
shown that other HPIs, such as atazanavir (ATV), 
can pharmacoenhance the intracellular accumula-
tion and area under the curve (AUC) of coadministed 
HPIs [2,29]. Published evidence to date suggests that 
ATV might be a substrate, or induces or inhibits P-gp, 
MRP and BCRP activities [2,3,23,25,30,31], but does 
not alter lymphocyte expression of P-gp, and MRP1 
[3,31]. The current study aims to characterize the 
determinants of the cellular transport and seques-
tration of [3H]-ATV in cultured CD4+ T-cells and in 
primary human lymphocytes – an important site to 
study the transport and intracellular concentration of 
antiretrovirals. Experiments were designed to under-
stand the lipophilicity and sequestration of [3H]-ATV 
within cells and the efflux and influx pumps relevant 
for the vectorial transport and retention of the drug.
Methods
Reagents
[3H]-ATV and [14C]-mannitol (specific activities 3.1 Ci/
mmol and 50 mCi/mmol, respectively) were purchased 
from Moravek Biochemicals and Radiochemicals (Brea, 
CA, USA). RTV and lopinavir (LPV) were obtained 
from Abbott Laboratories (North Chicago, IL, USA); 
nelfinavir (NFV), indinavir (IDV), SQV, amprenavir 
(APV), ATV and tipranavir (TPV) were obtained from 
Agouron Pharmaceuticals (San Diego, CA, USA), Merck 
(Rahway, NJ, USA), Roche (Welwyn Garden City, UK), 
Glaxo Wellcome (Middlesex, UK), Bristol–Myers Squibb 
(Hounslow, UK) and Boehringer Ingelheim (Berkshire, 
UK), respectively. Tariquidar was donated by Xenova 
Group Plc (Berkshire, UK). The peripheral blood mono-
nuclear cells (PBMCs) were isolated from blood buffy 
coats, which were obtained from the Regional Blood 
Transfusion Centre (Liverpool, UK). CEM (parental), 
CEMVBL (VBL) and CEME1000 (E1000) cell lines were 
from R Davey (Bill Walsh Cancer Research Laborato-
ries, Royal North Shore Hospital, Sydney, Australia). 
Lymphoprep was purchased from Axis Shields (Oslo, 
Norway). GPV031 was a gift from G Ecker (Depart-
ment of Medicinal Chemistry, University of Vienna, 
Vienna, Austria). All other chemicals were supplied by 
Sigma Chemical Co. (Poole, UK).
Cell culture
The cultured cells used in this study were CEM (a 
CD4+ T-cell line), VBL (P-gp overexpressing; selected 
using vinblastine) and E1000 (MRP-1 overexpress-
ing; selected using epirubicin). The expression of these 
transporters has been previously validated in our lab-
oratory [13]. The cells were maintained at 37°C, 5% 
CO2 in RPMI-1640 media supplemented with 10% 
fetal bovine serum (FBS).
Isolation of PBMCs 
PBMCs were isolated from blood buffy coats using Lym-
phoprep according to the manufacturer’s instructions.
Octanol/saline partition coefficient
As the cellular association of a drug within target cells 
is a composite of active influx/efflux, passive diffusion 
and ion trapping, the lipophilicity of [3H]-ATV was 
measured as described previously [6] to establish if sim-
ple physiochemical characteristics were major determi-
nants of intracellular accumulation.
Transport of [3H]-ATV and the effects of specific 
inhibitors on transport in CEM and CEMVBL cells
Initial experiments examined the optimal concentra-
tions of inhibitors for maximal inhibitory effects on Pgp, 
MRP and hOATP activity. Cells (CEM and its variant 
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cells) were incubated in the absence or presence of vary-
ing concentrations of XR9576 (0.01–1 µM; P-gp/BCRP 
inhibitor [32–34]), MK571, dipyridamole (1–100 µM; 
P-gp/MRP inhibitor [35,36]), frusemide (1–100 µM; 
MRP1/2 inhibitor [1], GF120918 (1–100 µM; P-gp/
BCRP inhibitor [13,37]), GPV031 (1–100 µM; P-gp 
inhibitor [38]), probenecid (1–100 µM; MRP/hOATP 
[14,39] and E-3-S (1–100 µM; hOATP/hOCTP inhibi-
tor [6,40]) as described [1].
In subsequent experiments, the transport and accu-
mulation of [3H]-ATV (20 nM) was measured by incu-
bating the cells (2.5×106 cells/ml) in the absence and 
presence of fixed concentrations of inhibitors: tariqui-
dar (1 µM), frusemide (50 µM), dipyridamole (50 µM), 
E-3-S (30 and 100 µM), probenecid (30 and 100 µM), 
GPV031 (30 and 100 µM) and GF120918 (50 µM). We 
also investigated the interaction of soy-derived phytoes-
trogens daidzein and genistein (at 1 and 5 mM) known 
to interact with P-gp, MRP, BCRP and hOATP [41–47] 
on the cellular accumulation ratio (CAR) of [3H]-ATV. 
The interaction of the HPIs, APV, IDV, LPV, NFV, RTV, 
SQV and TPV (all at 10 and 30 µM) on the transport 
and accumulation of [3H]-ATV was also investigated in 
CEM and its variant cells. All experiments were carried 
out in RPMI-1640 media supplemented with 10% FBS 
as described previously [1]. The amount of drug associ-
ated with the cells was quantified by taking a ratio of 
the amount of drug in the cell pellets to the amount 
of drug in a similar volume of the bathing media after 
incubation, taking cell volume (1 pl) into consideration. 
This ratio was defined as the CAR.
Accumulation of [3H]-ATV in isolated PBMCs and the 
effects of modulators of accumulation
The assay was carried out essentially as described 
above. Briefly, isolated PBMCs (5×106 cells/ml; cell vol-
ume 0.4 pl) were incubated in the absence or presence 
of fixed concentrations of the inhibitors: tariquidar 
(1 µM), GF120918 (50 µM), frusemide (50 µM), dipy-
ridamole (50 µM), GPV031 (30 and 100 µM), E-3-S 
(30 and 100 µM), and APV, IDV, LPV, NFV, RTV, SQV 
and TPV (all at 10 and 30 µM). In addition, we inves-
tigated the interaction of daidzein and genistein (1 and 
5 mM, respectively) on the CAR of [3H]-ATV.
Effects of digitonin permeabilization on the transport 
of [3H]-ATV
In order to characterize the energy dependence and 
accumulation of [3H]-ATV, drug transport assays were 
carried out in cells pretreated without or with 20 µM 
digitonin as described previously [48] followed by 
steady-state drug accumulation assay. Cells were incu-
bated with 20 µM digitonin prior to the addition of 
[3H]-ATV (20 nM), after which cells were incubated for 
a further 15 min. In other experiments, the cells were 
permeabilized by further incubating the incubation 
mixture with 20 µM digitonin for 5 min once steady-
state was reached (15 min).
Effects of ATV on daunomycin accumulation and 
efflux in cultured cells
Daunomycin is a substrate of P-gp and its accumulation 
and efflux were performed as described previously [38]. 
Concentration–response curves were fitted to the data 
points using non-linear least-squares and 50% effective 
concentration values were calculated as described pre-
viously [38].
Statistical analyses
Data are expressed as mean ±sd and the distribution 
of data was assessed using the Shapiro–Wilk test. Sta-
tistically significant differences between controls and 
drug-treated samples were further assessed using the 
Mann–Whitney U test of the StatsDirect statistical soft-
ware (version 2.6.3; Cheshire, UK). Differences between 
means were considered to be significant for P<0.05.
Results
Octanol/saline partition coefficient
The octanol/saline partition coefficient for [14C]-manni-
tol (used as control) and [3H]-ATV were 0.002 ±0.001 
and 29.90 ±4.12, respectively.
Transport of [3H]-ATV and the effects of inhibitors 
of drug efflux/influx transporters and digitonin on 
accumulation
As can be seen in Figure 1A, we observed differential 
accumulation of [3H]-ATV in the CEM, E1000 and VBL 
cells with the baseline CAR of CEM, E1000 and VBL 
cells being 11.2 ±0.9, 8.4 ±0.9 and 7.0 ±0.6, respectively. 
Tariquidar, dipyridamole and GPV031 (at 30 µM) 
significantly decreased (P≤0.05) the CAR of ATV in 
the CEM cells. Similarly, tariquidar and GPV031 (at 
30 µM), and daidzein (at 1 mM), significantly (P≤0.05) 
decreased the CAR of [3H]-ATV in the E1000 cells. 
Genistein significantly (P≤0.05) decreased the CAR of 
[3H]-ATV in the CEM and its variant cells. Tariquidar 
and GF120918 significantly (P≤0.05) increased the 
CAR of [3H]-ATV in the VBL cells, and daidzein (at 
5 mM) increased the CAR of [3H]-ATV in CEM and its 
variant cells (P<0.05). Frusemide, daidzein (at 1 mM) 
and genistein significantly (P≤0.01) decreased the 
CAR of [3H]-ATV in the VBL cells. E-3-S (at 30 µM) 
reduced the CAR of [3H]-ATV in E1000 and VBL cells 
(P<0.05), with 100 µM E-3-S causing a significant 
(P≤0.01) decrease in the CAR of [3H]-ATV in CEM and 
VBL cells. To characterize the contribution of specific 
cellular binding to total the accumulation of ATV, we 
investigated the effects of digitonin permeabilization on 
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Figure 1. Effects of modulators of drug transporters, digitonin and HPIs on the accumulation of [3H]-atazanavir in CEM, CEMVBL, 
CEME1000 and PBMCs
Effects of (A) modulators of drug transporters (tariquidar, dipyridamole, frusemide, GF120918, GPV031, daidzein, genistein, estrone-3-sulphate [E-3-S] and probenecid), 
digitonin and (B) HIV protease inhibitors (HPIs; amprenavir [APV], indinavir [IDV], lopinavir [LPV], nelfinavir [NFV], ritonavir [RTV] and saquinavir [SQV]) on the accumulation 
of [3H]-ATV in CEM, CEME1000 and CEMVBL cells. (C) Modulators of drug transporters (tariquidar, frusemide, dipyridamole, E-3-S, GPV031, daidzein and genistein) and HPIs (APV, 
IDV, LPV, NFV, SQV and tipranavir [TPV]) on the accumulation of [3H]-ATV in isolated peripheral blood mononuclear cells (PBMCs) from blood buffy coats. Bars indicate mean 
±sd (n=4, with 4 independent observations from cultured CEM and its variant cells and n=6, with 4 independent observations from each buffy coat PBMC sample). Results are 
expressed as cellular accumulation ratio (CAR), which is the ratio of the amount of [3H]-ATV associated with the cell pellets to the amount in a similar volume of media after 
incubation. P-values of aP<0.05, bP<0.001 and cP<0.01 indicate statistically significant differences (increases/decreases) in the CAR of [3H]-ATV as a result of coincubation with 
the compounds compared with control. Data were analysed by the Shapiro–Wilk test followed by the Kruskal–Wallis test.  
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accumulation. Here, cells were either initially permea-
bilized with 20 µM digitonin prior to the accumula-
tion studies or subsequent to the accumulation studies. 
We observed that permeabilization of CEM and E1000 
cells with digitonin significantly (P<0.05) reduced the 
accumulation of [3H]-ATV in these cells by 47% and 
30%, respectively. Unexpectedly, permeabilization of 
VBL cells with digitonin caused a significant (P<0.01) 
increase in accumulation (from 7.0 ±0.6 to 15.9 ±2.6; 
Figure 1A). Identical results were obtained in experi-
ments in which the effect of digitonin was assessed sub-
sequent to the accumulation studies (data not shown).
Effects of various HPIs on the accumulation of [3H]-ATV
RTV is used to boost the plasma concentration of a 
number of HPIs. Here, we investigated whether RTV 
and other HPIs could modulate the transport and accu-
mulation of [3H]-ATV in the CEM and its variant cells. 
Of the HPIs tested, only LPV (at 30 µM) significantly 
(P<0.01) increased the association of [3H]-ATV to the 
E1000 cells. We observed differential accumulation of 
[3H]-ATV in CEM, E1000 and VBL cells, with the fol-
lowing rank order: CEM>E1000>VBL. LPV and NFV 
(at 30 and 10 µM, respectively) significantly (P<0.05) 
decreased the accumulation of [3H]-ATV in the CEM 
cells. By contrast, LPV and RTV (at 30 µM) increased 
the accumulation of [3H]-ATV in the E1000 cells. In 
the VBL cells, the accumulation of [3H]-ATV was sig-
nificantly (P<0.01) reduced by APV, IDV and RTV (at 
30 µM). The uricosuric agent, probenecid (at 100 µM) 
significantly (P<0.05) increased the accumulation of 
[3H]-ATV in the E1000 cells, but had no effects on 
accumulation in CEM and VBL cells (Figure 1B).
Transport of [3H]-ATV in PBMCs and the effects of 
drug efflux inhibitors and HPIs on accumulation
We observed variable accumulation of [3H]-ATV in the 
PBMCs ranging from 13.6 ±1.5 to 24.9 ±1.9. We previ-
ously showed that PBMCs express P-gp, MRP, BCRP 
and hOATP [1,6]. Dipyridamole, E-3-S and GPV031 
caused a modest decrease in accumulation (Figure 1C). 
Interestingly, daidzein significantly increased (P<0.05), 
whereas genistein caused a significant (P<0.01) decrease 
in the CAR of [3H]-ATV. Unexpectedly, of all the HPIs 
tested, only TPV (at 30 µM) caused a modest (P<0.05) 
increase in the CAR of [3H]-ATV. APV, NFV, RTV and 
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SQV caused a decrease (P<0.05) in the CAR of [3H]-
ATV, either at both of the concentrations tested or at 
higher concentrations.
Effects of digitonin permeabilization on the transport 
of [3H]-ATV
Here, cells were either initially permeabilized with 
20 µM digitonin prior to the accumulation studies (in 
the absence or presence of inhibitors) or subsequently 
permeabilized upon carrying out the accumulation 
studies in the absence or presence of the inhibitors 
at steady state. As shown previously (Figure 1C), 
tariquidar and frusemide did not alter the accumula-
tion of [3H]-ATV, whereas dipyridamole significantly 
(P<0.01) decreased the accumulation of [3H]-ATV 
(Figure 2). Permeabilization of the cells with digi-
tonin significantly reduced (P<0.01) the accumulation 
of [3H]-ATV (from 15.3 ±0.8 to 13.0 ±0.1). Of the 
digitonin-pretreated cells that were subsequently coin-
cubated with tariquidar or frusemide, we observed no 
significant decrease in the CAR of [3H]-ATV compared 
with digitonin-treated samples. By contrast, there was 
a significant (P<0.05) decrease in the accumulation of 
[3H]-ATV in cells pretreated with digitonin followed by 
dipyridamole over cells treated with digitonin alone. 
Identical results were obtained with cells that were ini-
tially pretreated with the inhibitors and subsequently 
permeabilized with digitonin (data not shown). We 
also investigated the effects of E-3-S (alone and in the 
presence of tariquidar-, frusemide- or dipyridamole-
treated cells) on the accumulation of [3H]-ATV. E-3-S 
alone did not alter the CAR of [3H]-ATV. However, 
there was a significant (P≤0.01) decrease in the CAR 
of [3H]-ATV in cells pretreated with tariquidar, dipyri-
damole and frusemide, followed by subsequent E-3-S 
coincubation (Figure 2).
Atazanavir increases the accumulation and decreases 
the efflux of daunomycin in the cultured cells
ATV increased the accumulation and decreased the 
efflux of daunomycin in a concentration-dependent 
manner, with a 50% inhibitory concentration of 9.8 µM 
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Figure 2. Effects of modulators of drug transporters and digitonin, alone and in combination, on the accumulation of [3H]-ATV 
in PBMCs
Data were tested for normality of distribution by the Shapiro–Wilk test followed by a parametric paired t-test. Each bar represents the mean ±sd (n=3, with 4 
incubations per treatment). aP<0.01 and bP<0.05 compared with respective controls. ATV, atazanavir; CAR, cellular accumulation ratio; E-3-S, estrone-3-sulphate; 
PBMCs, peripheral blood mononuclear cells.
Janneh.indd   6 16/10/09   10:11:18
PROOF COPY ONLYPROOF COPY ONLY
Cellular uptake of atazanavir
Antiviral Therapy Page numbers not for citation purposes 7
and 8.5 µM, respectively (Figure 3). However, ATV had 
no effects on the accumulation and efflux of daunomy-
cin in the CEM line (data not shown).
Discussion
Here, we investigated the contribution of lipophilicity, 
efflux/influx mechanisms and embedding/sequestration 
in cell membranes to the accumulation of [3H]-ATV. 
We observed [3H]-ATV to be approximately 7× less 
lipophilic than [14C]-LPV, but 1.7× more lipophilic than 
[3H]-SQV [6]. The octanol/saline partition coefficient 
determined for [14C]-mannitol (our positive control) 
was similar to that reported previously [49].
Drug transporters are important determinants of 
variable drug accumulation, drug–drug interactions, 
efficacy, resistance and toxicity. There is ample evidence 
that some HPIs are substrates, inhibitors and inducers 
of drug transporters such as P-gp, MRP1/2, BCRP and 
hOATP/hOCTP [1,2,4,7–25,50]. However, the role of 
drug transporters in the accumulation of ATV has not 
been well documented [2,3,25,30,31]. In order to char-
acterize the transport profile of ATV, we studied its accu-
mulation in cultured cells and in primary human cells, 
with known transporter expression profiles [1,13]. These 
data provide evidence that ATV is a substrate of P-gp, 
and MRP1. This stems from the observations that there 
was differential accumulation of [3H]-ATV between 
CEM and its variant P-gp- and MRP1-overexpressing 
lines and that inhibitors of P-gp/BCRP (that is, tariquidar 
and GF120918) and P-gp/MRP (daidzein) increased the 
accumulation of [3H]-ATV in CEM and its variant cells. 
However, in contrast to the data obtained on other HPIs 
[1,2,13–15,51], the observation that tariquidar, dipyrida-
mole, frusemide, GF120918 and GPV031 all significantly 
decreased or did not alter the accumulation of [3H]-ATV 
in some or all of the cells (Figure 1A) was unexpected 
(Figure 1A and 1C). Although we found no direct evi-
dence that the influx of HPIs are sensitive to these drugs, 
and given that none of the drugs (at the concentrations 
and incubation times employed) are cytotoxic to the cells 
(data not shown), we postulate that the observed effects 
might be the result of inhibition of influx, competition 
for accumulation, or displacement of [3H]-ATV from 
cell membranes. Indeed, there is evidence that dipyrida-
mole and frusemide influence the fluxes or exchange of 
Na+, K+, Ca2+, Na+/H+ and Cl-/HCO3
- [52,53]. Given that 
E-3-S, a substrate/inhibitor of hOATP/hOCT [4,54], sig-
nificantly decreased the accumulation of [3H]-ATV, it is 
plausible that the accumulation of [3H]-ATV might be 
linked to the fluxes/exchange of these cations. Despite 
the recent observation that tariquidar does not inhibit 
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Figure 3. Concentration-dependent effects of atazanavir on the accumulation and efflux of daunomycin in CEMVBL cells
Concentration-dependent effects of atazanavir (0–50 µM) on the accumulation and efflux (inset; tariquidar at 0–200 µM) of daunomycin in CEMVBL cells. Initial efflux 
rates were determined from the slope of linear regression line fitted to mean fluorescence intensity values determined after 1, 2, 3 and 4 min. Initial daunomycin 
efflux rates are given as a percentage of the fluorescence values determined for the zero time point. Data points represent the mean of two independently performed 
experiments. The 50% inhibitory concentration IC50 values for the inhibition of efflux (8.5 µM; inset) and enhancement of accumulation (9.8 µM; inset) of daunomycin 
were calculated from the concentration–response curves using Grafit (Erithacus Software Ltd, Surrey, UK).
Janneh.indd   7 16/10/09   10:11:19
O Janneh et al.
©2009 International Medical Press8 Page numbers not for citation purposes
PROOF COPY ONLY PROOF COPY ONLY
hOATP1B3-mediated uptake of paclitaxel [55], it could 
also be possible that the effects of tariquidar on some 
of the cells might be the result of inhibition of an influx 
transporter not described elsewhere.
As with the cultured CEM and its variant cells, the 
effects of inhibitors of drug transport proteins on the 
intracellular accumulation of drugs in PBMCs might 
depend on the relative expression of the transporters. 
We recently showed the expression of several drug efflux 
transporters on PBMCs and demonstrated that the accu-
mulation of HPIs is amenable to modulation by inhibi-
tors of drug efflux and influx transporters [1,2,6]. Here, 
inhibitors of drug efflux transporters, such as tariquidar, 
dipyridamole, frusemide and E-3-S, produced contrast-
ing results to that measured for SQV and LPV [1,2]. 
The following possibilities might explain these observa-
tions: reduced cell surface expression of the efflux and 
influx transporters; important drug–drug interactions; 
the transporter profile of ATV differs from other HPIs 
– ATV is acid-sensitive to absorption, inhibits hepatic 
uridine 5′-diphospho-glucuronosyltransferase and 
induces CYPs [56,57]; and identification of some addi-
tional properties of some of the inhibitors used, such 
as frusemide and dipyridamole, might have potential to 
inhibit drug uptake transporters. Clearly, the decrease 
in the accumulation of [3H]-ATV by drugs such as fruse-
mide, dipyridamole and GPV031 (all known inhibitors 
of efflux transporters) warrants further investigations.
Soy-derived phytoestrogens, such as daidzein and gen-
istein, have been reported to interact with some major 
drug transporters, including P-gp, MRP, BCRP and 
hOATP [42–47,58]. However, their interactions with 
HPIs are largely undefined. We observed that daidzein 
had dual effects, with the agents causing modest but 
significant decrease (at 1 mM) and increase (at 5 mM) 
in accumulation of [3H]-ATV (P<0.05) in the cultured 
cells. In PBMCs, genistein decreased the accumulation of 
[3H]-ATV, whereas daidzein increased it. The observed 
effect of genistein is in agreement with the evidence that 
it inhibits an influx transporter, showing that it inhibits 
hOATP1B1- mediated uptake of [3H]-dehydroepiandros-
terone sulfate [45]. Furthermore, it has also been shown 
that genistein induces the depolarization of membrane 
potential [59], which might ultimately prevent the cellu-
lar accumulation of [3H]-ATV. As serum concentrations 
of phytoestrogens could be high [60], these data suggest 
that intake of soy tablets and or diets rich in soy might 
influence the accumulation, efficacy and toxicity of ATV. 
Taken together, these data suggest that these phytoestro-
gens are both inhibitors of influx and efflux transporters 
and that ATV might be a substrate of transporters that 
are affected by these phytoestrogens [42–47,58].
The evidence that E-3-S significantly decreased 
the accumulation of [3H]-ATV in the cultured cells 
suggests that ATV, like SQV and LPV [6] is also a 
substrate of hOATP. Although we observed that E-3-S 
alone did not decrease the accumulation of [3H]-ATV 
in the PBMCs (Figure 1C and 2), contrary to the lack 
of effects of tariquidar and frusemide alone (Figure 
1C and 2), coincubating tariquidar-, frusemide- and 
dipyridamole-treated cells with E-3-S significantly 
decreased the accumulation of [3H]-ATV (Figure 2). 
These observations indicate the potential for sig-
nificant drug–drug and drug–endogenous-substance 
interactions. We also observed that ATV enhances 
both P-gp-mediated accumulation and inhibits P-gp-
 mediated efflux of daunomycin in VBL cells (Fig-
ure 3). This is in some agreement with previous stud-
ies, which show that although ATV does not induce 
P-gp or MRP expression [31,61], it is an inhibitor of 
P-gp (and MRP [2,23,30] and is also able to increase 
the plasma concentration of coadministered HPIs [29] 
via blunting the activities of P-gp/MRP [2] and pos-
sibly cytochrome P450 enzymes [30].
RTV and other HPIs, including ATV, have been 
shown to modulate the plasma and intracellular con-
centrations of other HPIs [2,28,29] via inhibition of 
P-gp/MRP and cytochrome P450. Of the HPIs tested, 
only LPV and RTV (at 30 µM) increased the accumula-
tion of [3H]-ATV in E1000 cells (Figure 1B), whereas 
TPV (at 30 µM) significantly increased accumulation 
of [3H]-ATV in PBMCs (Figure 1C). There is evidence 
that some antiretrovirals, such as IDV, RTV, SQV and 
efavirenz, are potent inhibitors of uptake transporters 
(for example, hOATP1B1) or hOCTs [5,62,63]. Some of 
the HPIs (for example, APV, IDV and SQV) reduced the 
accumulation of ATV in the P-gp overexpressing VBL 
cells (Figure 1B and 1C). In a previous investigation, we 
observed that of the hOATP isoforms studied, only VBL 
cells express hOATP1A2 [6]. Given that some of these 
HPIs are also substrates of hOATP [6], it is probably 
that the inhibitory effects of some of the HPIs on the 
accumulation of ATV are a direct result of their com-
petition for entry into the cells with ATV. Overall, these 
observations plus that observed with probenecid suggest 
that ATV might be a substrate of uptake transporters. 
Thus its coadministration with some HPIs or probenecid 
might result in alterations in its cellular accumulation
Investigations that aim to characterize the role of 
drug transporters and the influence of drug embedding/
sequestering into cell membranes on the accumulation 
of [3H]-ATV in the cells using digitonin produced inter-
esting, but unexpected, findings. This manipulation 
decreased CEM-, E1000- and PBMC-associated [3H]-
ATV by 47%, 30% and 15%, respectively. However, 
a similar manipulation led to a significant increase in 
VBL-associated [3H]-ATV, suggesting the possibility that 
[3H]-ATV binds differentially to cells expressing differ-
ent and varying amounts of transporters, with the drug 
binding more avidly to P-gp- than MRP-overexpressing 
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cells. Another possibility is that [3H]-ATV might not be 
efficiently transported by P-gp and MRP. Coincubations 
containing digitonin-treated cells followed by subse-
quent treatment with tariquidar, frusemide or dipyrida-
mole were without any additional inhibitory effects over 
that observed with the inhibitors alone, suggesting lack 
of interaction between the coadministered agents.
In conclusion, we found that ATV is lipophilic, is a 
substrate of P-gp, MRP and hOATPs and is an inhibitor 
of P-gp, making its disposition susceptible to alteration 
by coadministered drugs and dietary components that 
interact with these transporters.
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